Evidence map›Paper›PMID 26405689›Full record

ArticleACS central science2015

Enantioselective Enzyme-Catalyzed Aziridination Enabled by Active-Site Evolution of a Cytochrome P450.

Christopher C Farwell, Ruijie K Zhang, John A McIntosh, Todd K Hyster, Frances H Arnold

Abstract read
In one paragraph

Article in ACS central science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Article
  2. Article
  3. Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026
    Review
  4. Review
  5. Synthesis and Application of Bioactive N-Functionalized Aziridines.Angewandte Chemie (International ed. in English) · 2025
    Review
  6. TransientSynlett : accounts and rapid communications in synthetic organic chemistry · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. SelectiveACS catalysis · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Enzymatic Nitrogen Incorporation Using Hydroxylamine.Journal of the American Chemical Society · 2023
    Article
  17. Article
  18. Article
  19. Engineering C-C Bond Cleavage Activity into a P450 Monooxygenase Enzyme.Journal of the American Chemical Society · 2023
    Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher C FarwellDivision of Chemistry and Chemical Engineering 210-41, California Institute of Technology , 1200 East California Boulevard, Pasadena, California 91125, United States.
Ruijie K ZhangDivision of Chemistry and Chemical Engineering 210-41, California Institute of Technology , 1200 East California Boulevard, Pasadena, California 91125, United States.
John A McIntoshDivision of Chemistry and Chemical Engineering 210-41, California Institute of Technology , 1200 East California Boulevard, Pasadena, California 91125, United States.
Todd K HysterDivision of Chemistry and Chemical Engineering 210-41, California Institute of Technology , 1200 East California Boulevard, Pasadena, California 91125, United States.
Frances H ArnoldDivision of Chemistry and Chemical Engineering 210-41, California Institute of Technology , 1200 East California Boulevard, Pasadena, California 91125, United States.

Funding

Hyster (Rivas-Souchet) Diversity SupplementR01GM127703 · NIGMS · PRINCETON UNIVERSITY · PI Todd Kurt Hyster · 2018 to 2026
$2.9M
Biocatalytic use of cytochrome P450 enzymesF32GM101792 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI MCINTOSH, JOHN ANDREW · 2012 to 2014
$150k
Evolution of p450's Machinery for C-H AminationF32GM108143 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HYSTER, TODD KURT · 2013 to 2014
$91k
NIGMS NIH HHS F32 GM101792NIGMS NIH HHS F32 GM108143NIGMS NIH HHS R01 GM127703
6 · The paper itself

Abstract

One of the greatest challenges in protein design is creating new enzymes, something evolution does all the time, starting from existing ones. Borrowing from nature's evolutionary strategy, we have engineered a bacterial cytochrome P450 to catalyze highly enantioselective intermolecular aziridination, a synthetically useful reaction that has no natural biological counterpart. The new enzyme is fully genetically encoded, functions

Identifiers

PMID26405689
PMCPMC4571169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.